It is a link to move within the page

History

1872 Tokubei Torii established a company named Uenoya, at Sakai-Machi, Yokohama, for import of pharmaceuticals from the West.
1909
Establishment of Uenoya's research laboratories, and start of dealing in Japanese pharmacopoeial drugs under the Torii brand name.

Establishment of Uenoya's research laboratories, and start of dealing in Japanese pharmacopoeial drugs under the Torii brand name.

1921(Nov.)
Uenoya reorganized as Torii Shoten K.K.

Uenoya reorganized as Torii Shoten K.K.

1949(May) Company name changed to Torii Pharmaceutical Co., Ltd.
1963(Apr.) Torii introduced ALLERGEN (allergenic extracts) an agent developed in-house for allergy diagnosis and immunotherapy.
1963(June) Torii went public with over-the-counter stock transactions at the Tokyo Securities Dealers Association.
1977(Oct.) A new plant constructed at Sakura, Chiba Prefecture, in accordance with GMP (Good Manufacturing Practices ) standards.
1979(Apr.)
Torii launched URINORM (benzbromarone), an agent for treatment of hyperuricemia and gout.

Torii launched URINORM (benzbromarone), an agent for treatment of hyperuricemia and gout.

1986(Oct.)
Torii launched FUTHAN (nafamostat mesilate), an in-house developed protease inhibitor, for injection.

Torii launched FUTHAN (nafamostat mesilate), an in-house developed protease inhibitor, for injection.

1990(Apr.) Current Head Office building completed.
1993(Oct.) Torii's stock listed on the second section of the Tokyo Stock Exchange.
1993(Nov.)
Torii launched ANTEBATE ointment and cream (betamethasone butyrate propionate), a topical adrenocortical hormone.

Torii launched ANTEBATE ointment and cream (betamethasone butyrate propionate), a topical adrenocortical hormone.

1995(Sept.) Torii's stock listed on the first section of the Tokyo Stock Exchange.
1998(Dec.) Japan Tobacco Inc.(JT) purchased more than 50% of Torii's stock.
1999(Oct.) JT and Torii established a collaboration arrangement (Torii concentrates on marketing and JT, on R&D.)
2005(Apr.)
Torii launched the anti-HIV drug Truvada Tablets (emtricitabine and tenofovir disoproxil fumarate), for which JT obtained import approval.

Torii launched the anti-HIV drug Truvada® Combination Tablets (emtricitabine and tenofovir disoproxil fumarate), for which JT obtained import approval.

2006(Apr.) The pharmaceutical manufacturing operations of the JT Group were consolidated at the Sakura Plant.
2009(Mar.)
Torii launched the oral antipruritis drug REMITCH CAPSULES (nalfurafine hydrochloride), for which Toray Industries, Inc. obtained manufacturing and marketing approval.

Torii launched the oral antipruritis drug REMITCH CAPSULES (nalfurafine hydrochloride), for which Toray Industries, Inc. obtained manufacturing and marketing approval.

2013(May)
Torii launched the anti-HIV drug Stribild Tablets (elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate), for which JT obtained manufacturing and marketing approval.

Torii launched the anti-HIV drug Stribild® Combination Tablets (elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate), for which JT obtained manufacturing and marketing approval.

2014(May)
Torii launched Riona Tablets (Ferric Citrate Hydrate) for the treatment of hyperphosphatemia, for which JT obtained manufacturing and marketing approval.

Torii launched Riona Tablets (Ferric Citrate Hydrate) for the treatment of hyperphosphatemia, for which JT obtained manufacturing and marketing approval.

2014(Oct.)
Torii launched “CEDARTOLEN SUBLINGUAL DROP - Japanese Cedar Pollen” a Sublingual Immunotherapy Drug for Japanese Cedar Pollinosis.

Torii launched “CEDARTOLEN SUBLINGUAL DROP - Japanese Cedar Pollen” a Sublingual Immunotherapy Drug for Japanese Cedar Pollinosis.

2015(Dec.)
Torii launched “MITICURE House Dust Mite Sublingual Tablets” an Allergen Immunotherapy Tablet for House Dust Mite Allergy

Torii launched “MITICURE House Dust Mite Sublingual Tablets” an Allergen Immunotherapy Tablet for House Dust Mite Allergy

2016(July)
Torii launched the anti-HIV drug Genvoya Tablets (elvitegravir/cobicistat/ emtricitabine/ tenofovir alafenamide), for which JT obtained manufacturing and marketing approval.

Torii launched the anti-HIV drug Genvoya® Combination Tablets (elvitegravir/cobicistat/ emtricitabine/ tenofovir alafenamide), for which JT obtained manufacturing and marketing approval.

2017(Jan)
Torii launched the anti-HIV drug Descovy® Combination Tablets (emtricitabine/tenofovir alafenamide), for which JT obtained manufacturing and marketing approval.

Torii launched the anti-HIV drug Descovy® Combination Tablets (emtricitabine/tenofovir alafenamide), for which JT obtained manufacturing and marketing approval.

It is the end of the page